Temsirolimus Clinical Trials

4 actively recruiting trials across 3 locations

▼ -1 trial since May 2026

Also known as: CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779 +1 more

Pipeline

Early 1: 1Phase 2: 2

Top Sponsors

Miller Children's & Women's Hospital Long Beach1
M.D. Anderson Cancer Center1
Canadian Cancer Trials Group1
American Society of Clinical Oncology1

Indications

Cancer4
Advanced Solid Tumors2
Lymphoma, Non-Hodgkin2
Multiple Myeloma2
Recurrent Sarcoma1

Other1 trial

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Phase 2

Birmingham, Alabama1 trial

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

University of Alabama at Birmingham Comprehensive Cancer Center

Phase 2

Long Beach, California1 trial

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

Miller Children's and Women's Hospital Long Beach

Early 1

Houston, Texas1 trial

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

M D Anderson Cancer Center

N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.